Background: To assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This requires that cost data be regularly updated. Objective and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in 2015 SEK. Results: A total of 1864 patients (mean age 56 years) participated in Sweden; 74% were below retirement age, and of these, 55% were employed. MS was reported to affect productivity at work in 78% of patients. Overall, 94% and 72% of patients felt that fatigue and cognition were a problem, respectively. The mean utility and costs were 0.757 and 244,000SEK at Expanded Disability Status Scale (EDSS) 0-3, 0.563 and 384,000SEK at EDSS 4-6.5 and 0.202 and 888,000SEK at EDSS 7-9, respectively. The average cost of a relapse was 36,900SEK. Conclusion: This study illustrates the burden of MS on Swedish patients and provides current data that are important for the development of health policies.
Introduction
Health economic studies have a long tradition in Sweden, and a number of cost of illness (COI) studies in multiple sclerosis (MS) have been published. [1] [2] [3] The introduction of disease-modifying treatments (DMTs), the establishment of comprehensive patient registries and the mandatory requirement for costeffectiveness analyses for new drugs 4 have made Sweden one of the most active countries for health economic studies.
The availability of new treatment options has led to changes not only in patient management but also to a focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 5 The most recent estimate puts prevalence at 189/100,000 based on a registered number of MS patients of 17,500 in 2008. 6 With earlier diagnosis after a clinically isolated event, 7 one must also expect a different distribution of the type of MS and the severity of the disease: a larger proportion of patients with relapsing-remitting disease and thus of patients in the early stages of Expanded Disability Status Scale (EDSS).
It is therefore important to update the information on the burden of MS, and this study is part of a Europeanwide effort in 16 countries, endorsed by the European Platform of MS Societies (EMSP) and carried out with the support of national MS Societies. It uses a similar methodology as the previous European survey in 2005 that also included Sweden. 3, 8 
Materials and methods
The detailed methodology for the European survey is published separately, as introduction to this series of country reports. 9 We therefore only provide a short summary of the general methods and issues specific to Sweden.
Data
The study aimed to estimate all costs related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement, invalidity). In addition, information on major symptoms such as fatigue and cognition (using visual analogue scale (VAS)), health-related quality of life (HRQoL) as well as self-assessed disability using descriptions based on the EDSS was collected.
Data were collected with a validated standard questionnaire, at a single point in time, for a retrospective time period. The latter was varied depending on the question to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses; 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS) and relapses, HRQoL and utility (EuroQol five dimensions (EQ-5D) 10 ) as well as fatigue, cognition and the effect of MS on work related during the current day or week. To ensure comparability across countries, utility scores were estimated with the original value set developed with the general population in the United Kingdom. 11 However, Sweden has produced its own tariff using a slightly different methodology where the value set was established using participants' own health state rather than hypothetical health states as in the United Kingdom. 12 This corresponds to the Swedish guidelines for economic evaluation where experience-based utility value sets are preferred. 4 The Swedish experience-based values are therefore also presented.
Costs
The costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for paying them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference in quarterly costs between patients with an EDSS of 0 -6 with or without a relapse; patients who were unsure were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation, as they are unlikely to be affected within 3 months.
The unit costs for the defined resource items were taken from public sources and are described in the paper on the methodology of the study, 9 and the results are reported in Swedish kronor (100SEK = €10.68, 2015 average).
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to allow analysis. This highlights how costs and HRQoL change as the disease progresses and provides the necessary data for cost-effectiveness analysis of treatments that are expected to change the course of the disease. As a consequence, our study population does not represent national prevalence of MS in Sweden, and the mean results for the sample are not meaningful. They can neither be extrapolated to national costs without careful adjustment nor can they be compared directly to the results in other studies. We therefore report the results by disease severity only.
Data collection
In anonymous surveys, it is difficult to include a fully representative patient population, and participation will heavily depend on the methods used for the survey: Collecting data in clinical MS centres tends to overestimate the number of patients with early disease and on treatment with DMTs; collecting data from members in a patient organisation may be influenced by the structure and the activities of the organisation. Internet surveys will bias towards early disease and patients with better education, while postal mails may bias towards older patients. In Sweden, a majority of patients are followed in the MS Registry, and contacting these patients would likely provide the least biased sample. However, as the European study was organised in collaboration with patient organisations, and as a number of studies were ongoing within the registry, patients were contacted by Neuroförbundet, as in the previous study in 2005. 3 The Swedish data were collected during the second half of 2015, after approval by the ethics committee (Regionala etikprövningsnämnden Stockholm). Neuroförbundet invited patients by electronic mail to participate in the on-line survey or to return a printed version by post. Surprisingly, the answer rate was extremely low, and after 1 month, we decided to send paper questionnaires for postal reply to 2663 members of Neuroförbundet. This resulted in an answer rate of 70%.
Results
A total of 1864 evaluable responses were received (207 on-line and 1657 on paper). All geographical regions were represented; 50.4% of respondents came from the regions around Stockholm, Uppsala, Malmö/ Lund/Helsingborg and Göteborg that represent around 60% of the Swedish population.
Within the European study, the Swedish sample was among the oldest and most severely affected. Age and EDSS drive the proportion of patients with relapsing disease indicated for DMT treatment, the number of patients actually on DMTs, to some extent the proportion reporting a relapse and the proportion of patients of working age. Thus, in Sweden, the proportions of patients with relapsing disease, on treatment with DMTs and reporting relapses as well as the proportion of patients of working age were in the lower range among the 16 countries. 13 Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Sweden ranged from 18 to 94 years (mean 56.2 years, median 57.0 years, SD 12.0 years); women represented 78%; 75% lived with their family and only eight patients were in a nursing home at the time of the survey. Education levels were comparable to the Swedish population: 12% of patients had basic education, 51% a secondary or a professional degree and 33% a university degree, compared to 10%, 57% and 31%, respectively, for women between 25 and 64 years of age, and 12%, 59%, 26% for the total population in this age group. 14 In the sample, 1371 patients (74%) were below effective retirement age (66 years for men and 64 years for women 15 ), and of these, 55% of patients were employed or self-employed. Twenty-five patients above retirement age also worked, bringing this group to 782 patients (or 42% of the full sample) with a mean age of 49.5 years. This compares to an employment rate of 77% in the Swedish population aged 25-64 years in 2014. 16 The majority of patients worked part-time (77%) for an average of 22.8 hours per week. This is considerably higher than in the general population where 29% of women and 9% of men work less than 34 hours. 17 Surprisingly, only 19% indicated that MS was the cause for part-time work. This may be explained by the high number of patients in the total sample who had at any time stopped working due to MS (52% of not employed patients).
However, 110 patients (14%) among employed patients were not actually working at the time of the survey, but were long-term sick listed (<3 and >12 months, mean 10.1 months), reducing the proportion of patients below retirement age actually working to 49%. Sick leave during the past 3 months was reported by 17% of patients, with a mean duration of 16.9 days. This compares to a national proportion of 4.5% for women and 2.7% for men during the fourth quarter in 2015. 18 Employment decreased rapidly with advancing disease, as shown in Figure 1 .
Most employed patients felt that MS affected their productivity at work (78%), and only 14% indicated that they had no problems, while 8% had not answered the question. The severity of the effect covered the entire VAS range from 0 to 10, with a mean of 3.6 (SD 2.7; Figure 2 ). Fatigue was considered the most disabling functional loss (70%), followed by difficulties thinking (34%), mobility (27%), pain (16%) and low mood (8%).
Disease information
The mean EDSS was 4.7 (SD 2.6), and all levels of EDSS were covered. Patients with mild disease (EDSS 0-3) represented 36%, patients with moderate disease (EDSS 4-6.5) 35% and patients with severe disease (EDSS 7-9) 28% ( Table 1 ). The proportion of patients with relapsing-remitting multiple sclerosis (RRMS) was 37.8% and with secondary progressive multiple sclerosis (SPMS) 30.3%. In view of the age of the sample, this is what can be expected. However, 23.7% of patients reported primary progressive multiple sclerosis (PPMS). This is high, particularly in view of the most recent data, 19 and attests to the difficulties for patients to distinguish between disease types, particularly SPMS and PPMS. Thus, we ignore the disease type in our analyses and focus instead on EDSS levels, despite the fact that DMTs are mostly indicated for relapsing disease.
DMTs were used by 42% of the sample, with usage declining with higher EDSS levels as expected (Table  1) . Among users, 28% were on their first DMT treatment. First-generation DMTs were used by 31% and newer DMTs by 66% (3% missing; Table 2 ).
Relapses in the preceding 3 months were reported by 155 patients (8.3%), of which 54% occurred in the past month. Corticosteroids were only administered to 22 patients with relapses, in 14 cases as infusion. However, a quarter of respondents were unsure whether they had a relapse or not, and we assumed that the answer was no. The mean number of relapses over a period of 3 months in the sample was thus estimated at 0.1 (SD 0.4)
Symptoms and HRQoL
Fatigue was an issue for 94% patients, with a mean VAS score of 5.7 (SD 2.4) for the sample and 5.3, 5.9 and 5.8 for patients with mild, moderate and severe diseases, respectively ( Figure 2 ).
Similarly, a majority of patients felt that they suffered from cognitive difficulties (72%). The mean VAS score among this group with difficulties was 5.0 (SD 2.1) and 4.7, 5.1 and 5.4 in the mild, moderate and severe groups, respectively. For the full study sample (assigning 0 to the group with no problems), the mean score was 3.7 (SD 2.9) and 3.5, 3.9 and 3.8 for the three groups, respectively ( Figure 2 ).
All five domains of HRQoL included in the EQ-5D were representing problems for a majority of patients, and difficulties increased with advancing disease as expected. Overall, 80% of patients experienced problems with pain/discomfort, 61% with mobility, 58% with usual activities, 53% with anxiety/depression and 26% with self-care. Self-care was only affected for patients with severe disease, while pain/discomfort and anxiety/depression are present already very early in the disease, indicating the difficulties in managing these symptoms (Figure 3 ). 
Utility
The utility declined with increasing disability (Figure 4 ). The mean utility in the sample was 0.563 and 0.771 using the UK and Swedish value sets, respectively.
Resource utilisation
Resource utilisation is presented in Table 3 . Healthcare resources (except medication) were collected for a 3-month period. Hospitalisation was very rare (3%), Figure 1 . Proportion of patients of working age employed or self-employed. Working age was defined as effective retirement age (64 years for women and 66 years for men; www.oecd.org). In all, 1371 patients (74%) were below retirement age, and of these, 55% were employed or self-employed. However, 110 patients were on long-term absence.
EDSS: Expanded Disability Status Scale. (Figure 5 ).
Costs
The total mean annual costs per patient for patients with mild, moderate and severe diseases and by EDSS score are presented in Figure 6 and Table 4 . The average cost of a relapse for patients with an EDSS of 0-6 was estimated at 31,500SEK, of which 48% were for hospital care, 15% for consultations and 12% for sick leave and informal care (Figure 7) .
Discussion
This study updates the findings of the earlier Swedish assessments of the burden of MS, 2,3 but incorporates recent research into MS-related symptoms.
Resource consumption and HRQoL show as expected the same correlation with EDSS as earlier studies: costs increase and utilities decrease with advancing disease severity. However, the structure of costs has changed, particularly in early disease where MS treatments constitute the majority of resources used. In addition, our data underpin the importance of fatigue as a major disabling symptom for patients. Almost all patients in our sample experienced fatigue. Still, fatigue appears often underestimated or ignored, but Figure 7 . Mean total 3-month costs for patients below EDSS 6.5 with and without a relapse (N = 118 and N = 720, respectively). Patients who were unsure (N = 472, 25% of the sample) or had not answered (N = 64, 3% of the sample) were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation, as they are unlikely to be affected within 3 months. The cost of a relapse is calculated as the difference between the two groups (36,900SEK), with hospital care responsible for 48% of the cost increase, consultations for 15% and sick leave and informal care 12% each.
EDSS: Expanded Disability Stats Scale; DMT: disease-modifying treatment.
may be one of the major factors hindering MS patients to remain in the workforce. In addition, fatigue has been shown to relate to cognitive difficulties, 13 and not surprisingly a majority of the sample indicated cognitive limitations. Similarly, pain was found to causing problems for patients at all stages of MS, at similar levels. This finding may indicate that like fatigue, pain is often underestimated, and also that this type of symptom is difficult to manage due to the lack of efficient drugs.
The clinical relevance of these findings is important. All patient groups displayed a time lag from first symptoms to diagnosis of 6-7 years. This may partially be due to the relatively high age of the sample with diagnoses given a number of years ago. However, in view of the importance of early treatment for preventing the development of disability, any delay in diagnosis is serious and must be avoided. Preventing of person with MS to reach higher EDSS scores would have a major impact on the quality of life and reduce cost of community care and production losses.
Patients in our study appeared rather unsure regarding the type of MS they had, confirming the finding in earlier studies. 8 This may indicate that patients are rarely told what disease subtype they have and illustrates the difficulty of self-assessment. This does not affect our analysis that focuses on EDSS rather than disease type. The conversion from RRMS to SPMS happens gradually over time and at different levels of EDSS for different patients.
The costs in our study are thus heavily dependent on the distribution of the sample over the EDSS range. In addition, although age is correlated with EDSS, it has an independent effect on production losses, as these are only relevant for patients below retirement age. As our Swedish sample does not represent national prevalence and has a relatively high mean EDSS and mean age, mean costs per patient are meaningless. We therefore present our results only by EDSS or in three groups of patients with mild, moderate and severe diseases.
For the same reason, a direct comparison of costs between this study and the earlier Swedish study in 2005 is not possible. Differences are due to a combination of factors related to the disease, and also to general trends in policy and healthcare services, and no causal effects can be derived. However, a number of observations can be made. The samples are not dissimilar, although patients in 2015 were slightly older but had less severe disease (mean age of 57 versus 53 years, mean EDSS 4.7 versus 5.1). The proportion treated with DMTs was the same (42% and 43%), and consultations were at a similar level. On the other hand, a higher proportion of patients reported relapses in the 2005 study (18% versus 8%) and inpatient admissions were more frequent (12% versus 3%). It is tempting to assume that this is a consequence of more effective treatments, but the data do not allow confirmation of this. Informal care was required by fewer patients in 2015 (44%) than in 2005 (57%), but the number of hours of assistance was higher.
Personal assistance was used by 13% of patients in the sample, for an average of around 400 hours per month. In 2005, a similar proportion of patients used the service, but for an average of 300 hours per month, despite the higher mean EDSS. 3 This increase may be explained by a general development of the service. The availability of personal assistants to patients with a handicap is a particular and very generous service established in Sweden in the early 1990s, but its costs are now being questioned. The total costs have increased from around 5 billion SEK in the early 1990s to 30 billion SEK today. The average approved hours of assistance per week doubled from 65 hours in 1994 to 130 hours in 2016, or 18 hours per day. 20 Workforce participation was high, considering the high age and the severity of the disease in the sample. However, as expected with high employment in a severe disease, a majority of patients worked parttime and a large proportion was on long-term sick leave. The same pattern was observed in 2005.
Sweden has been the only country that has applied a societal perspective for decisions on funding. 4 More recently, there have been discussions as to whether the inclusion of production losses discriminates against diseases that affect predominantly an elderly population. As a result, cost-effectiveness must now be estimated with and without production losses to comply with the reimbursement authorities' (TLV) ethical platform. 21 However, in MS where production losses represent around one-third of total costs in a young population, ignoring these costs does not appear reasonable.
Another recent point of discussion relating to costeffectiveness analyses in Sweden concerns utilities. Both the original and revised guidelines for economic evaluation state that experience-based utilities are preferred. 4, 22 Thus, it would appear that after the publication of the local experience-based value set, 12 this tariff should be used. However, there has been an intense debate as to whether the values established with the general population using descriptive hypothetical health states used in most countries or tariffs established with the population's own health states such as in Sweden should be used as reference. 23 In practice, both the UK and the Swedish tariffs are currently used. When comparing the utility curves in Figure 4 , it becomes apparent that experience-based values include coping with disease and adjusting lifestyle in severe and disabling disease. The question is whether this is what we should measure, rather than the actual perceived severity of a health state. 24 In conclusion, our study provides updated information on resource utilisation and costs in MS and confirms trends identified in earlier studies. However, it highlights the importance of MS-related symptoms such as fatigue, cognition and pain and suggests that the impact of these symptoms on HRQoL and also particularly on daily activities, workforce participation and support should be studied in greater depth.
